Foamy foot cream drug launches

Neubourg Pharma UK has launched Allpresan Diabetic Foot Foam Creams into the UK, clinically formulated to treat and prevent dry cracked skin and calluses on diabetic patient's  feet, the first clinically and medically approved to be used between toes safely.  

Until now, clinician advice for diabetics has been not to use creams between toes. Allpresan Diabetic Foam Creams have been clinically approved for safe usage on the entire foot including between the toes.  Unlike conventional creams, it is unique at protecting against the real risk of infection in this area.  

Allpresan Foam Creams are clinically formulated to treat and prevent dry skin on diabetic feet, reduce cracks and the build up of hard skin and calluses, counteract pressure marks and protect against infection and ulceration.  

This is achieved because of Allpresan’s patented actively breathable formula and unique moisturising complex of Urea, Pentavitin and Panthenol. When the foam is applied, it forms a two-dimensional protective mesh on the skin, so skin is able to breathe and is protected from external influences, such as bacteria.  

Dr Ivan Bristow, Faculty of Health Sciences, University of Southampton said:  “The importance of foot care for those with diabetes cannot be emphasized enough.  Regular foot checks can help identify complications early caused by diabetes.  Foot care including regularly applying cream to the foot can do several things – it  adds moisture to skin that is prone to dryness due  to reduced sweating and reduce the chances of developing cracked heels. Even the act of applying a cream means that a patient with diabetes  is aware of any changes to  the skin on their feet.”